
Altimmune’s New Avatar As A Liver Disease Player (NASDAQ:ALT)
DieterMeyrl/E+ via Getty Images Every time I take a fresh look at Altimmune (NASDAQ:ALT), it seems to have evolved into a new company. For a biopharma, its pipeline is the company; since Altimmune’s pipeline seems […]